1Dano K,Andreasen PA,GrondahlHansen J,et al.Plasminogen activators, tissue degradation and cancer[].Advances in Cancer Research.1985
2Reich R,Thompson EW,Iwamoto Y,et al.Effects of inhibitors of plasminogen activator serine proteinases, and collagenase Ⅳon the invasion of basement membranes by metastatic cells[].Cancer Research.1988
3Duffy MJ,Reilly D,O’Sullivan C,et al.Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer[].Cancer Research.1990
4Grondahl-Hansen J,Christensen IJ,Rose-nquist C,et al.High levels of urokin-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carci-no mas are associated with poor prognosis[].Cancer Research.1993
5Foekens JA,Schmitt M,Van Putten WLJ,et al.Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients[].Cancer Research.1992
6Duffy MJ,Reilly D,McDermott E,et al.Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer[].Cancer.1994
2Minicuci N,Noale M,Bardage C,et al.Cross-national determinants of quality of life from six longitudinal studies on aging:the CLESA project[J].Aging Clin Exp Res,2003,15(3):187-202.
3Fernandes JC,Martel-Pelletier J,Pelletier JP.The role of cytokines in osteoarthritis pathophysiology[J].Biorheology,2002,39(1-2):237-246.
4Malemud CJ,Islam N,Haqqi TM.Pathophysiological mechanisms in osteoarthritis lead to novel therapeutic strategies[J].Cells Tissues Organs,2003,174(1-2):34-48.
5Blanco FJ,Guitian R,Vázquez-Martul E,et al.Osteoarthritis chondrocytes die by apoptosis.A possible pathway for osteoarthritis pathology[J].Arthritis Rheum,1998,41(2):284-289.
6Wang Y,Lou S.Direct protective effect of interleukin-10 on articular chondrocytes in vitro[J].Chin Med J (Engl),2001,114(7):723-725.
7Tsutsui S, Ohno S, Murakami S, et al. Prognostic significance of the coexpression of p53 protein and c-erbB-2 in breast cancer[J]. The American Journal of Surgery, 2003,185(2) : 165.
8Zhang Liangfeng, Bewick, Mary Lafrenie, et al. EGFR and erbB2 differentially regulate Raf-1 translocation and activation[J]. Laboratory investigation, 2002,82(1) :71.
9Jalava PJ, Kuopio T, Kortelainen S, et al. Quantitation of erbB2 positivity for evaluation of high-risk patients[J]. Annals of medicine, 2002,34(7/8) :544.
